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ABSTRACT
Objective: This research was conducted to study the relationship between spleen status and chelation treatment status with the male reproductive 
hormones and some physiological parameter levels.
Methods: A total of 35 males with thalassemia major (TM) patients are recruited. Patients are grouped according to (1) their age into two groups; 
˂18 years and ≥18 years, (2) their spleen status into two groups; splenectomize and non-splenectomize, and (3) their chelation treatment status into 
two groups; regulation and irregulation. Body mass index (BMI) was calculated and blood was collected from all patients just before blood transfusion 
session. Hb, ABO blood groups,  ferritin, and hormone (luteinizing hormone [LH],  follicle-stimulating hormone [FSH],  testosterone, prolactin, and 










β-Thalassemia  is a serious genetic disorder that  leads  to a significant 
increase in both morbidity and acute and chronic mortality, especially 
in  our  developing  countries,  for  at  least  the  next  few  decades  [1,2]. 
In  the  past,  children  with  the  disease  rarely  succeed  to  survival 
after  adolescence  [3].  In  the  late  1970s,  quality  of  the  patient’s 
life was improved due to introduction of optimal red blood cell 
transfusions  [4],  but  severe  endocrine  complications  are  developed 
in  patients  with multitransfused  due  to  iron  overload  [5].  The main 
reason for iron overload is increased iron absorption in the intestine 
due to it’s requested by the body to produce new erythrocytes rather 
than  the  inefficient  [6]  or  due  to  transfusions  sometimes  [7].  Iron 
overload  caused  many  complications.  One  of  these  complications  is 
hypogonadism in thalassemia patients [8,9].
Other  complication  of  β-thalassemia  includes  hyperactivity  of  spleen 
(hypersplenism)  which  leads  to  splenomegaly.  Splenomegaly  is 
characterized by an increase in mechanical filtration of spleen and early 
destruction of blood components [10].
Splenectomy  and  almost  daily  subcutaneous  chelation  are  the  main 
therapies to reduce hemolysis resulting increase the lifespan of red 
cell, eliminate the need for regular transfusions, prevent the risk of iron 
overload [11], and normalize reproductive and sexual life [12].
Although  thousands  of  people  over  the  world  have  β-thalassemia 
and  suffer  from  problems  in  the  reproductive  health,  literature  on 
these  issues  is  rare,  especially  the  relationship  between  the  type  of 
treatment and  the sexual health. Hence,  this  research aimed  to study 
the  relationship  between  spleen  status  (splenectomize  or  not)  and 





A  total  of  35  Iraqi  male  with  beta-thalassemia  major  (TM)  patients 
are  recruited  from  thalassemia  center/Children’s  Teaching  Hospital, 
Kerbala/Iraq,  at  the  age  of  14–29  years.  All  patients  are  blood 
transfusion dependent (20 ml packed RBCs/kg, at 2–3 weeks interval) 
to maintain  a  pretransfusion  hemoglobin  concentration  above  8  g/l; 
also,  all  of  them were  on  iron  chelation  therapy.  A written  informed 
patient consent was taken from all the volunteers in the study. The age, 
blood groups, spleen status, and treatment status are recorded from the 
profile of all patients. Patients are grouped according to:
1.  Their age into two groups; ˂18 years and ≥18 years
2.  Their  spleen  status  into  two  groups;  splenectomize  and  non-
splenectomize
3. Their chelation treatment status into two groups; regulation and 
irregulation.
The  body  weights,  by  body  balance,  and  height,  by  paper  tape,  of 
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At morning  and  after  taking  consent,  5 ml  blood was  collected  from 
all  patients  2–3  weeks  after  the  previous  transfusion.  Hb  level  was 
determined by gemmy hematocrit. Then, the rest of blood was collected 
in  a dry  sterilized  test  tube. The blood  samples were  centrifuged  for 
5 min at 3000 rpm to obtain the serum that used to determine:














Results  are  expressed  as mean ±  standard  error  or  percentage. Data 
were  analyzed  by  one  sample  test  for  percentages  and  by  Student’s 
t-test  for  other  parameters  comparison  using  Statview  version  5.0. 
Differences were considered significant when p<0.05.
RESULTS
Table  1  showed  the  basic  clinical  manifestations  of  TM  patients, 
in which there were only significant differences between the 
frequencies  of  blood  groups,  the  highest  frequency  was  Group  O 
and the lowest was AB. The rest parameters showed non-significant 
differences.
The result of estimated parameters in all groups is showed in Table 2; 
it showed that TM patients aged ˂18 years have significant higher Hb 
value than those who aged ≥18 years while TM patients aged ≥18 years 
have  significant  higher  BMI  value.  However,  ferritin  showed  non-
significant difference between the two groups of TM patients.




the treatment irregularly have significant higher BMI and ferritin 
values compared to who take the treatment regularly. However, the rest 
parameters showed non-significant differences.
Table  3  showed  the  results  of  hormones  in  all  groups,  in  which  TM 
patients aged ≥18 years have high  level of LH, FSH, and  testosterone 
compared to patient aged ˂18 years, but only the difference in LH and 
testosterone levels reached the significant.
TM  patients  without  splenectomize  have  higher  FSH,  prolactin,  and 
testosterone  compared  to  patients with  splenectomize,  but  only  FSH 
and prolactin reached the significant.




Thalassemia was described as a severe anemia type which associated 
with splenomegaly and changes of bone marrow in children by Cooley 
and  Lee  [14].  Blood  transfusion  is  the  available  treatment  of  these 
patients  [15],  but with  the  time,  it  leads  to many  complications  [16] 






is  very high,  but  in AB blood group  is  very  low  in Bagdad/Iraq  [20]. 
The same results were reported by Mohammad et al. in Iran [21] and 
in our previous research [22], while Saha and Sahadalal [23] and Iqbal 




Many studies reported that children with TM suffer from many 
complications which  including growth retardation,  impaired  immune 
function,  and  low  BMI  [25-27].  It  is  well  established  that  the  BMI 
was  influenced by many parameters  including age, gender, endocrine 
Table 1: The basic clinical manifestations of TM patients


















Table 2: Estimation of parameter’s level in both groups of TM patients according to age, and spleen and treatment status
Characters Hb (g/dl) BMI (kg/m²) Ferritin (ng/ml)
Age
˂18 years 9.3±0.3* 17.7±0.5 2788.2±421.4
≥18 years 8.6±0.2  19.5±0.5* 3265.9±442.03
p value 0.045 0.031 0.51
Spleen status
Splenectomize 8.97±0.24 19.8±0.43* 3125.0±493.8
Non-splenectomize 8.81±0.23 17.96±0.64 3427.0±466.3
p value 0.721 0.0165 0.68
Treatment status
Regular 8.87±0.31 17.9±0.64 2002.3±394.9
Irregular 8.95±0.21 19.96±0.44* 3604.7±436.3*
p value 0.840 0.0245 0.0238
*Significant differences between two groups
215
Asian J Pharm Clin Res, Vol 12, Issue 5, 2019, 213-216
 Jouda et al. 
system  status,  and  nutrition  [28].  Fung  et al. [29]  reported  that  the 
underweight status increased among childhood and adolescence 
with thalassemia. The reasons can be the presence of hypogonadism, 
undernutrition  [30-32],  and  the  side  effects  of  chelation  treatment, 
which  used  to  decrease  iron  level  in  these  patients  [33].  In  our 
results, BMI was higher in TM patients aged ≥18 years, in TM patient 
who  takes  the  chelation  treatment  irregularly,  and  TM  patients with 
splenectomize compared to TM patients aged ˂18 years, TM patients 
who  take  the  chelation  treatment  regularly,  and  TM  patients  with 
non-splenectomize,  respectively. TM patients who  take  the  treatment 
irregularly have also significant higher ferritin values compared to who 
take the treatment regularly.
In  the  classic  knowledge,  iron  accumulated  in  the  pituitary  gland  of 
thalassemia patients results a cytotoxic effect. These cytotoxic effects 
result  to  hyporesponsiveness  of  pituitary  gland  to GnRH  and  lead  to 
hypergonadotrophic  hypogonadism  [34],  which  can  appear  as  low 
estradiol  or  testosterone  with  LH  and  low  FSH  [8].  Iron  overload  is 






Glandular insufficiency does not respond to late chelation treatment 
of  the  disease  [37],  but  prepuberty  chelation  therapy  has  helped 
patients  get  natural  sexual maturity  in  some  studies  [8].  In  contrast, 
another study reported that there was no difference in the frequency of 
pluripotent maturity when treatment began with iron ingestion at the 
age of 10 or earlier [18]. However, with modern drugs, iron deficiency 
glands may be reversible with iron intensive chelation systems [8]. In 
our  results,  TM  patients  take  the  chelation  treatment  regularly  have 
significantly higher testosterone levels and non-significantly lower FSH 
level compared to who take treatment irregularly.
The  hypothalamic-pituitary-gonadal  axis  is  strongly  involved  in 
regulating the immune system. There is a link between the gonads and 
the spleen. Han et al.[38] reported that the deprivation of testosterone 
by  surgical  castration  increases  GnRH  and  many  immune  cytokine 
expressions in the spleen. Immune castration increases the production 
of  GnRH  in  the  spleen  by  eliminating  the  effects  of  the  inhibitory 
reactions  of  testosterone,  thereby  improving  the  immune  markers 
of  the  immune  cytokines  of  the  spleen  and  serum  [38-40].  This  can 
explain  the high  level  of  testosterone  and prolactin  in  splenectomize 
thalassemic patients in this study.
It seems that hyperprolactinemia does not participate in the cause 
of  hypergonadotrophic  hypogonadism  in  thalassemia  patients  [30]. 
Plasma levels of prolactin were within the normal range of all male 
and  female  hypogonadal  patients  [32].  In  this  study,  there  were  no 
differences in the prolactin levels according to age and treatment status.
The usual tests of adrenal function in patients with thalassemia have 
shown little weakness in function but have always worked at maximum 
rate to produce normal levels of cortisol spread [33]. Landon et al. [41]
showed a very large suppression of function in the physiological range 
with a normal function reserve using the more gradual physiological 
cortical  stimulation  test  [34].  This  could  explain why  there were  no 
differences  in  thalamic  patients  according  to  age,  and  treatment  and 
spleen status.
CONCLUSION
The levels of cortisol and prolactin hormones are not disturbed in TM 
patients and not associated with the rate of transfusion, but the level of 
Hb and ferritin leads to underweight in BMI and may lead to endocrine 
dysfunction,  especially  sexual  hormones  (FSH,  LH,  and  testosterone). 
These  BMI  and  sex  hormones  are  related  to  age,  and  spleen  and 
treatment status.
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